Kawai, M.; Tomita, K.; Akiyama, T.; Okano, A.; Miyagawa, M. Preparation of Polycyclic Pyridone Derivatives as Cap-Depend-ent Endonuclease (CEN) Inhibitors and Prodrugs Thereof. Jpn. Tokkyo Koho, JP5971830, 2016.
Shishido, T.; Noshi, T.; Yamamoto, A.; Kitano, M. Medicine for Treating Influenza Comprising a Combination of Cap-Depend-ent Endonuclease Inhibitor with Anti-Influenza Drug. PCT Int. Appl, 201803246, 2017.
Noshi, T.; Kitano, M.; Taniguchi, K.; Yamamoto, A.; Omoto, S.; Baba, K.; Hashimoto, T.; Ishida, K.; Kushima, Y.; Hattori, K.; et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus poly-merase PA subunit. Antivir. Res. 2018, 160, 109–117.
Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.; et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2018, 8, 9633.
Koszalka, P.; Farrukee, R.; Mifsud, E.; Vijaykrishna, D.; Hurt, A.C. A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions. Influenza Other Respir. Viruses 2020, 14, 460–464.
Hughes, D.L. Review of the Patent Literature: Synthesis and Final Forms of Antiviral Drugs Tecovirimat and Baloxavir Mar-boxil. Org. Process Res. Dev. 2019, 23, 1298–1307.
Jackson, D.; Elderfield, R.A.; Barclay, W.S. Molecular studies of influenza B virus in the reverse genetics era. J. Gen. Virol. 2011, 92, 1–17.
Yuan, S.; Wen, L.; Zhou, J. Inhibitors of Influenza A Virus Polymerase. ACS Infect. Dis. 2018, 4, 218–223.
Ju, H.; Zhang, J.; Huang, B.; Kang, D.; Huang, B.; Liu, X.; Zhan, P. Inhibitors of Influenza Virus Polymerase Acidic (PA) Endo-nuclease: Contemporary Developments and Perspectives. J. Med. Chem. 2017, 60, 3533–3551.
Kawaguchi, N.; Koshimichi, H.; Ishibashi, T.; Wajima, T. Evaluation of Drug-Drug Interaction Potential between Baloxavir Mar-boxil and Oseltamivir in Healthy Subjects. Clin. Drug Investig. 2018, 38, 1053–1060.
Heo, Y.-A. Baloxavir: First Global Approval. Drugs 2018, 78, 693–697.
Hsu, A.C.-Y. Influenza virus: A master tactician in innate immune evasion and novel therapeutic interventions. Front. Immunol. 2018, 9, 743/1–743/11.
Takashita, E.; Daniels, R.S.; Fujisaki, S.; Gregory, V.; Gubareva, L.V.; Huang, W.; Hurt, A.C.; Lackenby, A.; Nguyen, H.T.; Pereyaslov, D.; et al. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018. Antivir. Res. 2020, 175, 104718.
Koszalka, P.; Tilmanis, D.; Roe, M.; Vijaykrishna, D.; Hurt, A.C. Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012–2018. Antivir. Res. 2019, 164, 91–96.
Hayden, F.G.; Sugaya, N.; Hirotsu, N.; Lee, N.; de Jong, M.D.; Hurt, A.C.; Ishida, T.; Sekino, H.; Yamada, K.; Portsmouth, S.; et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N. Engl. J. Med. 2018, 379, 913–923.
Fukao, K.; Noshi, T.; Yamamoto, A.; Kitano, M.; Ando, Y.; Noda, T.; Baba, K.; Matsumoto, K.; Higuchi, N.; Ikeda, M.; et al. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. J. Antimicrob. Chemother. 2019, 74, 654–662.
Koshimichi, H.; Ishibashi, T.; Kawaguchi, N.; Sato, C.; Kawasaki, A.; Wajima, T. Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings. Clin. Drug Investig. 2018, 38, 1189–1196.
Data Available on the RxList Website and in Xofluza® Package Insert. Available online: https://www.ema.europa.eu/docu-ments/product-information/xofluza-epar-product-information_en.pdf (accessed on 10 December 2021).
Koshimichi, H.; Tsuda, Y.; Ishibashi, T.; Wajima, T. Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients with Influenza. J. Pharm. Sci. 2019, 108, 1896–1904.
Ison, M.G.; Portsmouth, S.; Yoshida, Y.; Shishido, T.; Mitchener, M.; Tsuchiya, K.; Uehara, T.; Hayden, F.G. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): A randomised, placebo-controlled, phase 3 trial. Lancet Infect. Dis. 2020, 20, 1204–1214.
Hawkes, N. Sixty seconds on baloxavir. BMJ 2018, 363, k4531.
Kuo, Y.-C.; Lai, C.-C.; Wang, Y.-H.; Chen, C.-H.; Wang, C.-Y. Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials. J. Microbiol. Immunol. Infect. 2021, 54, 865– 875.
Ishiguro, N.; Morioka, I.; Nakano, T.; Furukawa, M.; Tanaka, S.; Kinoshita, M.; Manabe, A. Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to <12 years with influenza: An open-label, randomized, active-controlled trial protocol. BMC Infect. Dis. 2021, 21, 777.
Chong, Y.; Kawai, N.; Tani, N.; Bando, T.; Takasaki, Y.; Shindo, S.; Ikematsu, H. Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season. Antivir. Res. 2021, 192, 105092.
Liu, J.-W.; Lin, S.-H.; Wang, L.-C.; Chiu, H.-Y.; Lee, J.-A. Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis. JAMA Netw. Open 2021, 4, e2119151.
Takashita, E. Influenza polymerase inhibitors: Mechanisms of action and resistance. Cold Spring Harb. Perspect. Med. 2021, 11, a038687.
Sato, M.; Takashita, E.; Katayose, M.; Nemoto, K.; Sakai, N.; Fujisaki, S.; Hashimoto, K.; Hosoya, M. Detection of variants with reduced baloxavir marboxil and oseltamivir susceptibility in children with influenza A during the 2019–2020 influenza season. J. Infect. Dis. 2020, 222, 121–125.
de Haas, E.C.; Luijendijk, H.J. Baloxavir for influenza: Enrichment obscured lack of effect in North-American adults. Eur. J. Intern. Med. 2019, 62, e8–e9.
de Haas, E.C.; Luijendijk, H.J. Baloxavir for influenza: Enrichment obscured lack of effect in North-American adults. Author’s reply. Eur. J. Intern. Med. 2020, 72, 102.
Li, G.; De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 2020, 19, 149–150.
